Author: Groeneveld, Geert H; van der Reyden, Tanny J; Joosten, Simone A; Bootsma, Hester J; Cobbaert, Christa M; de Vries, Jutte J C; Kuijper, Ed J; van Dissel, Jaap T
Title: Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial Document date: 2019_5_18
ID: 19ueli6e_48
Snippet: To identify transcripts with the highest discriminatory power between pneumococcal versus other infections, PLS-DA was run and VIP scores were calculated. The transcripts with the five highest VIP scores are shown in Figure S1 . Only chemokine (C-C motif) ligand 5 (CCL5) was statistically significant lower 24 h after the start of treatment in patients with pneumococcal pneumonia versus patients with non-pneumococcal pneumonia. Treatment with or w.....
Document: To identify transcripts with the highest discriminatory power between pneumococcal versus other infections, PLS-DA was run and VIP scores were calculated. The transcripts with the five highest VIP scores are shown in Figure S1 . Only chemokine (C-C motif) ligand 5 (CCL5) was statistically significant lower 24 h after the start of treatment in patients with pneumococcal pneumonia versus patients with non-pneumococcal pneumonia. Treatment with or without rifampicin did not significantly affect the results.
Search related documents:
Co phrase search for related documents- non pneumococcal pneumonia and treatment start: 1
- pneumococcal pneumonia and rifampicin treatment: 1, 2, 3, 4, 5, 6, 7
- pneumococcal pneumonia and treatment start: 1, 2, 3, 4, 5, 6, 7
- result affect and significantly result affect: 1
- result affect and treatment start: 1
- rifampicin treatment and treatment start: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date